What is the purpose of this trial?
This is an international, multi-center, open-label, phase II study in patients with metastatic urothelial cancer after failure of platinum-based regimen or anti-PD-1 /PD-L1 based immunotherapy.
Approximately 140 patients are anticipated to be enrolled across approximately 50 sites from North America and Europe.
Ages: 18 years and older
Start Date: 11/14/2018
End Date: 12/31/2021
Last Updated: 12/06/2018
Study HIC#: 2000023211